Pazopanib: An antiangiogenic drug in perspective

Carlos A. Castaneda, Henry L. Gomez

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

22 Citas (Scopus)

Resumen

Pazopanib, a tyrosine kinase inhibitor targeted to angiogenesis, has been tested in preclinical and clinical trials and has shown promising activity against a variety of solid tumors, such as renal cancer, all of which are related to the angiogenic pathway. It has a safety profile related to this mechanism of action. Diarrhea, hypertension, hair depigmentation and nausea are the most common side effects. Pazopanib is currently under evaluation as monotherapy and in combination with some potentially synergistic agents of proven activity.

Idioma originalInglés
Páginas (desde-hasta)1335-1348
Número de páginas14
PublicaciónFuture Oncology
Volumen5
N.º9
DOI
EstadoPublicada - 2009

Huella

Profundice en los temas de investigación de 'Pazopanib: An antiangiogenic drug in perspective'. En conjunto forman una huella única.

Citar esto